The Impact of Pediatric Skin Disorders: The "Big" Study
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Chronic Pediatric Skin Conditions
- Sponsor
- Northwestern University
- Enrollment
- 1666
- Locations
- 1
- Primary Endpoint
- Measure the stigma experienced by children as a function of the child's perceived skin lesion visibility using the altered Neuro-QoL stigma tool
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
This study leverages the availability of a validated series of instruments to measure the effect of highly visible, chronic skin disorders, including atopic dermatitis (AD), on patients 8 years of age and above in causing stigma and psychiatric issues, particularly anxiety and depression.
Detailed Description
This is a multi center study with Northwestern University/Lurie Children's Hospital serving as the Data Coordinating Center. Site selection has been completed through members of PeDRA.
Investigators
Amy Paller
Principal Investigator
Northwestern University
Eligibility Criteria
Inclusion Criteria
- •Subjects must be aged 8-17 years of age
- •Subject must be diagnosed with a chronic skin disease deemed to be severe enough and/or in a visible location that could be stigmatizing as determined by the study doctor
- •Subject and parent must both be English speaking with at least one parent/guardian who will complete the questionnaires
- •Subject and Parent/Guardian must be able to complete the relevant questionnaires
Exclusion Criteria
- •Children under 8 years of age
- •Children with developmental delay and/or a behavioral disorder that would preclude participation in form completion
- •Children with a non-cutaneous disorder that is considered by the Study doctor to be stigmatizing
Outcomes
Primary Outcomes
Measure the stigma experienced by children as a function of the child's perceived skin lesion visibility using the altered Neuro-QoL stigma tool
Time Frame: Past 7 days
Measure the stigma experienced by children as a function of the child's perceived skin lesion visibility using the altered Neuro-QoL stigma tool